Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

CSL Provides Annual Research And Development Investor Briefing

04 Dec 2019  |  08:39:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: Research and Development Investor Briefing 2019

CSL provided 2019 annual research and development investor briefing. It reported on activities focused on new therapies for life-threatening diseases. The Company noted that Haptoglobin Prevents Vasospasms Induced by Haemorrhagic CSF. CSL346 is a novel humanised monoclonal antibody (IgG4) that binds VEGF-B.

Please click here for full details

See more ASX300 News Announcements